What are the approved indications, dosing regimens, monitoring requirements, and safety considerations for upadacitinib in pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Upadacitinib in Pediatric Patients

Upadacitinib is FDA-approved for pediatric patients aged 2 to <18 years with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis, and for adolescents ≥12 years weighing ≥40 kg with moderate-to-severe atopic dermatitis. 1

Approved Pediatric Indications

Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Psoriatic Arthritis

  • Age range: 2 to <18 years
  • Approval basis: Extrapolation from adult rheumatoid arthritis and psoriatic arthritis data, supported by pharmacokinetic modeling in 51 pediatric JIA patients and safety data from 83 pediatric patients 1
  • Clinical efficacy: In the SELECT-YOUTH trial, JIA ACR 30/50/70/90/100 responses at week 12 were 91.8%, 89.8%, 69.4%, 49.0%, and 32.7% respectively, with efficacy maintained through week 48 2

Atopic Dermatitis

  • Age range: ≥12 years weighing ≥40 kg
  • Approval basis: 344 adolescents (12-17 years) studied across three trials, showing efficacy consistent with adults 1
  • Clinical efficacy: In pediatric patients, adverse reaction profile was similar to adults 1

Not Approved

  • Ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, and Crohn's disease have not been established as safe or effective in pediatric patients 1
  • However, emerging real-world data suggests potential benefit in refractory pediatric IBD, though 43.8% of patients relapsed after transitioning from induction to maintenance dosing 3

Dosing Regimens

Weight-Based Dosing Strategy

Body weight-based dosing is used to achieve plasma exposures comparable to effective adult doses 1, 4:

  • Oral solution (immediate-release): Twice-daily dosing for younger children or those unable to swallow tablets
  • Extended-release tablets: Once-daily dosing for children who can swallow tablets
  • Pharmacokinetic profile: Median Tmax is 2-4 hours for ER tablets and 0.5-2 hours for IR solution; functional half-life is shorter with IR solution (2-5 hours) versus ER tablets (5-8 hours) 5, 2

Critical consideration: Upadacitinib clearance decreases with decreasing body weight in pediatric patients, necessitating weight-based dose adjustments 1, 5

Formulation Considerations

  • RINVOQ tablets and RINVOQ LQ are NOT bioequivalent and are NOT interchangeable on a milligram-per-milligram basis 1
  • Food has no clinically relevant effect on absorption (can be taken with or without food) 1

Monitoring Requirements

Pre-Treatment Screening

  1. Pregnancy testing: Verify pregnancy status in females of reproductive potential before starting treatment 1
  2. Tuberculosis screening: Screen for latent TB and active infections before initiation 6
  3. Baseline laboratory assessment: Obtain baseline complete blood count, liver function tests, and lipid panel

Ongoing Monitoring

Based on adult monitoring recommendations that apply to pediatric patients 6:

  • Infections: Monitor for signs of serious infections throughout treatment, particularly in patients ≥65 years (though this primarily applies to adult populations, vigilance for infections is warranted in all ages)
  • Laboratory monitoring:
    • Important caveat: For JAK inhibitors that interfere with IL-6 signal transduction (including upadacitinib), CRP-based disease activity instruments should be used with caution as these drugs directly suppress CRP production, potentially masking inadequate disease control 7
    • Monitor complete blood counts and liver enzymes periodically
    • Lipid monitoring as clinically indicated

Drug Interactions Requiring Dose Adjustment

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): Increase upadacitinib exposure by 75%; consider dose reduction 1
  • Strong CYP3A4 inducers (e.g., rifampin): Decrease upadacitinib exposure by 61%; consider dose increase during TB treatment 6, 1
  • Renal impairment: Mild-to-moderate renal impairment requires no dose adjustment; use not recommended in severe renal impairment 1
  • Hepatic impairment: Mild-to-moderate hepatic impairment requires no dose adjustment; not studied in severe hepatic impairment (avoid use) 1

Safety Considerations

Pediatric-Specific Safety Profile

In clinical trials, upadacitinib was generally safe and well-tolerated in pediatric patients, with no new safety signals compared to adults 5, 2:

  • Most common adverse events (≥3 patients): Upper respiratory tract infection, COVID-19 infection, headache, abdominal discomfort, vomiting, asthma, and cough 5
  • Severity: Adverse events were predominantly mild to moderate 2
  • Serious adverse events: 6 of 57 patients in the JIA trial experienced serious adverse events over median exposure of 412 days 2

Contraindications and Warnings

Absolute contraindications:

  • Severe active infections (acute or chronic, including latent TB and opportunistic infections) 6
  • Pregnancy (embryolethality and cardiovascular malformations observed in animal studies at 5.6-15 times human exposure) 1

Relative contraindications requiring shared decision-making:

  • Active malignancy or recent malignancy (within 5 years in most clinical trials) 6
  • Severe organ dysfunction 6

Special Populations

Females of reproductive potential:

  • Use effective contraception during treatment and for 4 weeks after the final dose 1
  • Upadacitinib may cause embryo-fetal harm 1

Breastfeeding:

  • Breastfeeding is not recommended during treatment and for 6 days (approximately 10 half-lives) after the last dose 1
  • Animal data shows drug exposure 30-fold greater in milk than maternal plasma 1

Geriatric Considerations (Relevant for Transition Planning)

While primarily applicable to adults, note that patients ≥65 years showed higher rates of serious infections and malignancies, particularly with 30 mg dosing 1. This becomes relevant as pediatric patients transition to adult care.

Long-Term Safety Considerations

  • Infection risk: Serious infection rates comparable to adalimumab in adult studies, with higher rates at higher doses 6
  • Malignancy: No malignancy signal detected in registries and clinical trial data to date 6
  • Zoster risk: JAK1-selective inhibitors may have reduced zoster risk compared to pan-JAK inhibitors 7

Emerging Real-World Evidence

Off-label use in children <12 years with severe atopic dermatitis: A 2026 case series of 9 children with dupilumab-refractory severe AD showed median EASI decrease from 21 to 2 at week 24, with 78% achieving EASI-75 and rapid pruritus improvement (NRS 7 to 1), though this remains off-label 8

Pediatric IBD: Real-world data suggests potential benefit but high relapse rates (43.8%) after transitioning to maintenance dosing, indicating pediatric patients may require longer induction periods or higher maintenance doses than adults 3

References

Related Questions

Can upadacitinib (Rinvoq) be prescribed to a 14‑year‑old patient with psoriatic arthritis?
What is the appropriate dosing regimen for ethosuximide in a 6‑year‑old child weighing about 20 kg, including starting dose, titration schedule, maintenance range, and adjustments for renal or hepatic impairment?
How is Rinvoq (upadacitinib) administered?
What is the recommended treatment regimen for pediatric ulcerative colitis, including induction and maintenance therapy?
Is it appropriate to use upadacitinib (Rinvoq) for an 84‑year‑old man with severe atopic dermatitis when dupilumab (Dupixent) is unavailable?
What are the current updates on the relationship between chronic spontaneous urticaria and gastritis, including H. pylori screening and management?
What are the recommended adjustments to other diabetes medications when adding insulin, glucagon‑like peptide‑1 receptor agonist (GLP‑1 RA), or sodium‑glucose cotransporter‑2 inhibitor (SGLT2i)?
Is dinoprostone vaginal gel safe for use in a patient with long QT syndrome?
Does fentanyl have a higher affinity for μ‑opioid receptors than morphine?
Can oxytocin be used in a patient with long QT syndrome?
In a 70-year-old patient with paroxysmal atrial fibrillation and a platelet count of 150,000 per microliter who is unwilling to take apixaban 5 mg twice daily, should a reduced-dose apixaban, a short‑term direct oral anticoagulant regimen, or left atrial appendage occlusion be recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.